Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Related Keywords

Spain ,Denmark ,Barcelona ,Comunidad Autonoma De Cataluna ,Copenhagen ,Køavn ,Enriqueta Filip ,Department Of Oncology Vall ,Hebron University Hospital ,European Lung Cancer Congress ,Lung Cancer ,Strategy After ,Lung Cancer Congress ,Pembrolizumab Versus Standard ,Sitravatinib With Nivolumab ,Patients With Nonsquamous ,After Checkpoint Inhibitor Therapy ,Atezolizumab ,Cabozantinib ,Non Small Cell Lung Cancer ,Nsclc ,Felcc ,Nct04471428 ,